Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy
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TO THE EDITOR
After the first report by Kamel et al 1 in 1993 about rheumatoid arthritis (RA)-associated lymphomas regressing after withdrawal of methotrexate, there is increasing concern about the role of methotrexate (MTX) in developing such malignancies. A particular group of RA-associated lymphomas may share common characteristics with post-transplant lymphoproliferative disorders (PT-LPD). 2 We report the case of a fulminant polyclonal B cell, EBV-positive lymphoproliferative disorder occurring in a patient with juvenile rheumatoid arthritis under MTX. Long-term remission was achieved after MTX withdrawal and treatment with anti-CD20 monoclonal antibody.
A 38-year-old woman with severe juvenile RA since the age of 9, was referred for febrile neutropenia and polyadenopathy. Treatment consisted of MTX 10 mg/week for 10 months, sulfasalazine 2 g/day for 10 years, hydroxychloroquine 400 mg/day for 20 years and nonsteroidal anti-inflammatory drugs. Sjö gren's syndrome was never identified. Exacerbated polyarthralgias led to an increase of MTX to 15 mg/week 5 weeks before admission. The polyarthralgias suddenly resolved concomitantly with development of polyadenopathies, 3 weeks before admission. On clinical examination she had high fever (39°C) and diffuse voluminous inflammatory lymph nodes. Whole body CT scanning was unremarkable. Peripheral blood (PB) examination showed neutropenia at 0.5.10 × 
, CD79a
+ immunoblasts, with plasmacytic differenciation for some of them. Mature CD138
− plasma cells were also present (Figures 1 and 2 ). No light chain restriction could be evidenced by immunohistochemistry and IgH rearrangement by polymerase chain reaction (PCR) amplification did not detect clonality. A bone marrow aspirate showed granulopoiesis arrest on promyelocyte-myelocyte stage, some rare large + BM plasma cells was normal and fluorescent in situ hybridization for del(13q)/−13 and der(14)t(11;14) was negative. IgG were increased at 52 g/l and polyclonal. C-reactive protein was normal. Direct Coombs test was IgG positive, C3d negative without sign of hemolysis. Anti-neutrophils IgG antibodies were strongly positive on indirect immunofluorescence with an unknown specificity. Epstein-Barr virus (EBV) serology was positive for IgG with anti-VCA and anti-EBNA specificities and negative for IgM. Peripheral blood EBV-PCR was strongly positive. LN immuno-histochemistry was negative for LMP-1 expression, but some immunoblastic cells were positive for EBER1, 2 and BHLF-1 mRNAs expression by in situ hybridization (Figure 3 ). Search for EBV clonality by Southern blot analysis performed on the LN was negative. HHV-8, CMV, HIV, HBV and HCV serologies were negative. The diagnosis of EBV-related polyclonal B cell lymphoproliferation was established. All drugs, including MTX, were discontinued. Ten days later, neutro- This is the first time that anti-CD20 antibodies have been used in this particular setting, without chemotherapy. Stewart et al 3 recently published the case of an EBV-related non-Hodgkin's lymphoma (NHL) occurring in a patient with RA and successfully treated with Rituximab. However, this NHL occurred in the setting of a B cell chronic lymphocytic leukemia and could not be directly related to RA. Moreover, remission was achieved with both polychemotherapy and Rituximab. The LPD in our case was revealed by an autoimmune neutropenia. Lymphoproliferation was particular with an expansion of immunoblasts of B cell phenotype in the LN (Figures 1 and 2 ) and circulating plasma cells that initially suggested a diagnosis of plasma cell leukemia. All techniques used for clonality assessment were negative. The relation to EBV was affirmed by EBER1, 2 and BHLF-1 mRNAs expression in the LN (Figure 3 ) and positivity for EBV-PCR in the blood. BHLF-1 positivity indicated replicative ongoing EBV infection. We could not detect monoclonal EBV genomic material in the LN of this patient by Southern blot. The presence of anti-EBNA antibodies at diagnosis excluded a primo-infection to EBV.
Patients with RA are considered at increased risk of developing lymphomas among other neoplasms. In addition to chronic activation of the immune system by the autoimmune disorder, EBV-specific T cell function seems to be defective in RA 4 and EBV-infected B cells are increased. Immunosuppressive therapy for RA may further increase the relative risk of developing lymphomas from 2.5 to 10. 5 These lymphomas are often EBV-positive. 6 MTX may favor the emergence of LPDs and EBV positivity may be predictive of success of MTX withdrawal. 7 However, it is still uncertain whether there is a real increase in the incidence of lymphoma while taking MTX. 8 The above data support evidence for the existence of a subgroup of RA-associated LPDs resembling PT-LPDs in polymorphic histology, EBV positivity and possible regression after reduction of immunosuppressive therapy. By analogy to PT-LPDs, the polyclonal character of LPD in our case offers further insights into the natural history of LPDs occurring in RA. Therapeutic results in PT-LPDs could be extrapolated to RAassociated LPDs. In the literature, the delay in response after MTX withdrawal was usually short. In the absence of a rapid response, clinicians almost always proceeded to chemotherapy administration. Progression of the LPD in our case, despite MTX withdrawal, led us to rapidly introduce anti-CD20 antibody therapy. Rituximab has proven efficacy in PT-LPDs. 9 Complete response was obtained in our case with a presumed action on the CD20
+ immunoblastic compartment and a subsequent decrease in the more mature derived CD20 − plasmacytic compartment. The response was rapid and progressively − cell population and their identification has been hampered by the laborious isolation procedure and the small yield of cells obtained by the various methods of isolation used so far. Therefore, a priority is to search for cell lines with HSC characteristics in order to facilitate research in this area.
Expression of CD133 on a human cell line lacking CD34
In 1994, we established a new fibroblast like cell line, designated GM-490, from the bone marrow of a patient with acute lymphoblastic leukaemia. 5 GM-490 cells have a morphology typical of adherent fibroblasts. GM-490 cells express CD29, CD36, CD71, CD54, CD105 surface antigens but lack CD34, CD38, HLA-DR, CD45, CD14 and all lymph-
